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Abstract	
The	population	of	elderly	 individuals	with	rheumatoid	arthritis	 is	rapidly	expanding,	mainly	
due	to	the	increased	life	expectancy.	While	targeted	biological	therapies	are	well	established	
for	the	treatment	of	this	disease,	their	use	may	be	 lower	 in	elderly	(>	of	65	years	old)	and	
very	elderly	patients	(>	75	years	old)	due	to	perceived	higher	risks	for	adverse	events	in	this	
population	 taking	 into	 account	 comorbidity,	 polypharmacy	 and	 frailty.	 In	 this	 review	 we	
discuss	available	evidence	 for	 the	use	of	biological	 therapies	 in	 this	growing	patient	group	
with	 specific	 attention	 towards	 eventual	 reasons	 for	 biological	 treatment	 failure	 or	
withdrawal.	 The	 majority	 of	 data	 is	 found	 in	 secondary	 analyses	 of	 clinical	 trials	 and	 in	
retrospective	 cohorts.	 Most	 information	 is	 available	 about	 tumor	 necrosis	 factor	 (TNF)	
blockers.	 Older	 patients	 seem	 to	 have	 a	 less	 robust	 response	 to	 anti-TNF	 agents	 than	 a	
younger	 population,	 but	 drug	 survival	 that	 may	 considered	 a	 proxy	 for	 efficacy	 does	 not	
seem	to	be	influenced	by	age.	Despite	an	overall	rate	of	adverse	effects	comparable	to	that	
in	 younger	 patients,	 elderly	 RA	 patients	 are	 at	 higher	 risk	 of	 serious	 infections.	 Other	
biologics	 appear	 to	 have	 an	 efficacy	 similar	 to	 anti—TNF	 agents,	 also	 in	 the	 elderly	 RA	
patients.	Again,	 the	drug	 survival	 rates	 for	 tocilizumab,	 rituximab	and	 abatacept	 resemble	
those	 in	 young	 RA	 patients	 with	 good	 general	 tolerability	 and	 safety	 profiles.	 The	
cardiovascular	risk	and	the	risk	of	cancer,	increased	in	RA	patents	and	in	the	elderly	patients,	
do	not	appear	to	be	strongly	influenced	by	biologicals.		
Key	points	
- Biological	 drugs	 targeting	 specific	 cytokines	 or	 immune	 cell	 populations	 are	 an	
important	 part	 of	 the	 management	 strategy	 for	 rheumatoid	 arthritis	 patients,	
including	the	elderly.	
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- Overall	safety	and	tolerability	in	the	elderly	patients	is	very	good	and	age	should	not	
be	a	critical	factor	to	decide	against	biological	drug	use.	
- The	drug	survival	rate	of	biologicals	in	the	elderly	RA	patients	is	comparable	to	that	in	
the	young	RA	population.	
- Co-morbidities	 and	 risk	 of	 infection	 are	 important	 variables	 to	 assess	 when	
considering	a	biological	drug	in	the	elderly.	
- More	data	and	specific	studies	are	required	to	better	position	biological	drug	use	in	
this	particular	population	as	current	studies	provide	a	low	level	of	evidence.	Data	in	
patients	 above	 75	 years	 are	 still	 largely	 missing.	 Moreover,	 the	 group	 of	 elderly	
patients	 that	were	 included	 in	 clinical	 trials	may	be	 influenced	by	 selection	bias	 at	
inclusion	and	not	be	fully	representative	for	infections	risks	and	other	comorbidities.	
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1. Introduction	
Rheumatoid	 arthritis	 (RA)	 is	 a	 chronic	 systemic	 auto-immune	 disease	 that	 is	 clinically	
characterized	 by	 symmetrical	 polyarthritis	 [1].	 Current	 estimates	 suggest	 a	 disease	
prevalence	of	0.5	to	1%	of	Caucasian	populations,	slightly	less	in	Asian	populations	[2,	3]	and	
overall	 more	 rare	 in	 Africans	 [4,	 5].	 Not	 only	 genetic	 but	 also	 environmental	 factors,	
including	 shorter	 life-span	may	 play	 a	 role	 in	 such	 differences	 in	 prevalence.	Women	 are	
about	 three	 times	 more	 affected	 then	men.	 Peak	 age	 of	 onset	 for	 women	 is	 considered	
between	50	and	60	years	whereas	for	men	it	is	suggested	to	be	over	70	years	[6].		
With	the	increased	life	expectancy	and	quality	of	life,	the	number	of	older	patients	with	RA	is	
steadily	 increasing	 in	 the	 Western	 world,	 representing	 10-33%	 of	 all	 RA	 cases	 	 [7].	 The	
overall	prevalence	of	RA	in	older	persons	(≥60	years)	 is	estimated	around	2%	and	reaching	
up	to	2.8%	after	70	years	[8].		
The	 World	 Health	 Organization	 suggests	 to	 define	 an	 elderly	 person	 as	 having	 a	
chronological	 age	 of	 65	 years	 or	 above	 (WHO.	 Definition	 of	 an	 older	 or	 elderly	 person.	
www.who.int/healthinfo/survey/ageingdefnolder/en.).	The	use	of	calendar	age	to	define	an	
older	individual	is	somewhat	arbitrary,	as	it	assumes	equivalence	with	biological	age.	Aging	
in	 humans	 is	 however	 a	 complex	 dynamic	 and	 multidimensional	 process	 and	 cannot	 be	
denoted	 as	 a	 simple	 dot	 on	 a	 timeline.	 	 It	 correlates	with	 changes	 in	 physical,	 social	 and	
psychological	 status	 and	 progressive	 functional	 decline.	 Gradual	 decrease	 in	 renal	 and	
hepatic	 function,	 diminished	 total	 body	 water	 and	 albumin	 levels,	 increased	 body	 fat	
contribute	to	many	important	changes	including	modifications	in	drug	pharmacokinetics	and	
pharmacodynamics	 [9].	 Elderly	 patients	 with	 RA	 suffer	 more	 from	 comorbidities	 such	 as	
hypertension,	 diabetes	mellitus,	 chronic	obstructive	pulmonary	 and	 cardiovascular	disease	
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than	 younger	patients	 [10],	 often	 resulting	 in	polypharmacy	 and	an	 increased	 risk	of	 drug	
interactions.	 Specific	 geriatric	 conditions,	 such	 as	 cognitive	 impairment,	 depression,	
malnutrition,	sensory	 limitations,	mobility	restrictions	and	incontinence	result	 in	decreased	
functional	 capacity	 and	 reduced	 ability	 to	 withstand	 or	 compensate	 for	 acute	 or	 chronic	
illness	 [11].	The	concept	of	 frailty	 is	used	to	define	an	 inevitable	multifactorial	progression	
toward	functional	decline.	It	involves	multiple	systems	and	manifests	as	wasting	(weight	loss	
and	 loss	 of	 muscle	 mass),	 decrease	 in	 performance	 (physical	 and	 cognitive),	 loss	 of	
endurance,	 inactivity	 and	 sensorial/physical	 impairment.	 Frailty	 leads	 to	 important	
vulnerability	of	older	patients,	higher	 risk	of	 infections,	 falls,	hospitalizations	and	mortality	
[12].	
During	aging,	 the	highly	sophisticated	and	 finely	 tuned	 immune	system	undergoes	marked	
changes,	known	as	immunosenescence.	This	affects	both	the	innate	as	well	as	the	adaptive	
arms	of	 the	 immune	 system	and	 results	 in	 a	decreased	 capacity	 to	 resolve	 infections,	 but	
also	 in	 pro-inflammatory	 changes	 and	 breaks	 in	 self-tolerance.	 The	 aging	 of	 the	 innate	
immune	system	leads	to	the	dysregulation	of	dendritic	cells	(DCs),	neutrophils,	Natural	Killer	
(NK)	 cells	 and	macrophages	with	 increased	 production	 of	 pro-inflammatory	 cytokines	 and	
higher	 circulating	 levels	 of	 TNF,	 IL-6,	 C-reactive	 protein	 (CRP)	 and	 other	 pro-inflammatory	
molecules,	 creating	 a	 pro-inflammatory	 environment	 [11,	 13];	 this	 process	 is	 described	
sometimes	as	“inflammaging”	[14]	.			
The	most	 striking	 changes	 probably	 take	 place	 in	 the	 adaptive	 immune	 system.	With	 the	
thymic	involution	and,	presumably,	ageing	of	hematopoetic	stem	cells	(HSC)	due	to	reduced	
telomerase	 activity	 and	 shift	 in	 HSC	 subpopulations,	 the	 generation	 of	 new	 T	 cells	
progressively	declines.	The	latest	elicits	compensatory	proliferation	of	peripheral	naïve	and	
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memory	T-cells,	known	as	homeostatic	proliferation	[13].		The	proportion	of	naïve	regulatory	
T	 cells	 decreases	 with	 age,	 but	 their	 absolute	 numbers	 stay	 relatively	 stable	 as	 the	
proportion	 and	 the	 absolute	 numbers	 of	 memory	 T	 cells	 increase.	 Additionally,	 the	 total	
CD4+T	cell	counts	significantly	increase	with	age	and	CD8+T	cell	counts	decrease,	resulting	in	
significantly	raised	CD4/CD8	ratio	in	elderly	subjects	[15].	Furthermore,	both	T	cells	subsets	
undergo	changes	in	their	receptor	expression	and	thereby	in	their	function.	In	a	nutshell,	the	
contracted	 T	 cell	 receptor	 (TCR)	 repertoire	 and	 loss	 of	 CD28,	 a	 pivotal	 co-stimulatory	
receptor	 necessary	 for	 T	 cell	 activation	 and	 proliferation,	 result	 in	 marked	 phenotypic	
changes.	 The	CD4+CD28-	 cells	may	acquire	NK-like	 functionalities	 [16],	produce	more	pro-
inflammatory	 	 cytokines	 and	 become	 resistant	 to	 apoptosis	 [17].	 These	 cells	 are	 prone	 to	
react	 with	 self-antigens	 and	 it	 comes	 as	 no	 surprise	 that	 CD4+CD28-	 populations	 are	
increased	 in	 several	 auto-immune	 diseases,	 RA	 in	 particular	 [11].	 The	 CD8+CD28-	 cells	
become	unable	to	produce	cytokines,	but	acquire	the	ability	to	suppress	antigen-presenting	
function	of	DCs.	Major	 repercussions	of	 the	aging	of	 the	 immune	system	are	an	 increased	
risk	of	infectious	diseases,	reduced	response	to	vaccination	and	raised	risk	of	cancer.	The	risk	
of	autoreactivity,	as	discussed	earlier,	also	increases	with	age	and	autoantibodies	are	more	
frequently	detected	in	the	elderly	population	[18].		
The	aim	of	this	paper	was	to	review	and	critically	discuss	the	literature	available	for	the	use	
of	biological	 therapies	 in	 the	elderly	 (>	65	years)	and	very	elderly	 (>	75	years)	RA	patients	
with	specific	attention	towards	eventual	reasons	for	therapy	failure	or	withdrawal.	We	also	
identify	 some	 important	 practical	 considerations	 for	 the	 use	 of	 biologics	 in	 this	 specific	
population.	
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2. Rheumatoid	arthritis	in	the	elderly		
Interestingly,	RA	 is	 characterized	by	accelerated	signs	of	 immunosenescence,	 regardless	of	
disease	duration	or	 the	age	of	onset	 [11].	Changes	observed	 in	 the	 immune	 system	of	RA	
patients	are	similar	to	those	in	the	elderly,	leading	ultimately	to	breach	of	self-tolerance.	Just	
like	 in	 older	 individuals,	 telomere	 shortening	 in	 the	 lymphocytes	 [19],	 T-cell	 aging	 and	
emergence	 of	 CD28-	 cells	 are	 seen	 in	 RA	 patients	 [13].	 But	 whether	 these	 changes	
suggesting	immunosenescence	are	a	cause	or	a	consequence	of	RA	is	still	unclear.		
This	 raises	 the	 question	 whether	 there	 are	 differences	 between	 RA	 in	 young	 and	 elderly	
patients	 and	 whether	 these	 affect	 the	 management	 strategies?	 Generally,	 older	 patients	
have	more	comorbidities,	cognitive	impairment	and	present	with	geriatric	syndromes	due	to	
age	but	also	as	a	consequence	of	RA	and	its	eventual	treatment	[20].		
Functional	disability	also	increases	with	advancing	age	[20]	and	longer	disease	duration	[21-
23].	 In	 addition,	 female	 gender,	 high	 baseline	 disease	 activity,	 elderly	 onset,	 multiple	
comorbidities	[21],	especially	cardiovascular	disease,	are	also	associated	with	disability	and	
lower	 quality	 of	 life	 [24].	 Impaired	 kidney	 and	 liver	 function	 and	 polypharmacy	may	 also	
contribute	to	worse	prognosis	in	the	seniors	with	RA.	These	issues	all	make	the	assessment	
and	 the	management	of	RA	 increasingly	complex.	Of	note,	depression	 in	RA	patients	does	
not	correlate	with	age	[25]	and	contributes	to	functional	disability	[21].	
Some	 intriguing	 studies	 are	 available	 comparing	 young-	 and	 elderly	 onset	 RA.	 Younger	
patents	 often	 have	 higher	 baseline	 disease	 activity	with	 higher	 swollen	 joint	 count,	 acute	
onset	 and	 higher	 ESR	 and	 CRP	 levels	 [26].	 The	 proportion	 of	 patients	 positive	 for	
characteristic	 auto-antibodies	 such	 as	 the	 rheumatoid	 factor	 and	 anti-citrullinated	 protein	
antibodies	 in	 this	 group	 is	 lower	 [27,	 22].	 Initially,	 they	 tend	 to	 have	 more	 radiographic	
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damage	[28,	26],	but	radiographic	progression	itself	appears	independent	of	age	[26,	28,	27].	
More	radiological	damage	and	higher	disease	activity	at	baseline,	as	well	as	positive	anti-CCP	
antibodies	 are	 predictors	 of	 radiological	 progression	 in	 early	 onset	 patients	 [29].	 	 Older	
patients	 [29,	 21],	 are	 less	 likely	 to	 achieve	 remission;	 female	 gender	 and	 higher	 baseline	
DAS28	lower	their	chances	of	achieving	this	clinical	response	[27].	Older	patients		also	tend	
to	have	higher	functional	disability	[24].	
As	discussed,	the	risk	of	infection	increases	with	age	but	RA,	especially	when	presenting	with	
extraarticular	 manifestations,	 and	 its	 treatment	 also	 largely	 contribute	 to	 this	 risk.	
Moreover,	 patients	 residing	 in	 rural	 areas,	with	 ≥	 2	 comorbidities,	 chronic	 lung	 and	 renal	
disease	and	previous	infection	are	particularly	at	risk	[30].	Furthermore,	RA	doubles	the	risk	
for	myocardial	 infarction	and	stroke,	 increasing	death	 from	cardiovascular	disease	by	30%.	
Although,	 the	 relative	 risk	 is	 highest	 in	 younger	patients,	 the	 absolute	 rate	 is	 increased	 in	
older	 age	 categories	 [31],	 and	 cardiovascular	 problems	 are	 the	 number	 one	 cause	 of	
mortality	 in	 elderly	 RA	 patients	 [32].	 Finally,	 patients	 with	 RA	 have	 an	 increased	 risk	 of	
cancer	 [33],	 especially	 Hodgkin’s	 and	 non-Hodgkin	 lymphoma,	 non-melanoma	 skin	 cancer	
(NMSC)	 [34,	 35]	 and	 possibly	 lung	 cancer	 [36].	 The	 rate	 of	 colorectal	 and	 breast	 cancer	
however	seems	to	be	lower	than	in	general	population[33].	
3. 	Treatment	of	elderly	RA	in	the	XXI	century	
Despite	comparable	and	sometimes	higher	disease	activity,	some	studies	show	that	elderly	
RA	patients	 receive	 less	 aggressive	 treatment	 [22,	 37,	 38].	 This	may	be	dependent	on	 the	
local	setting	as	according	to	others,	the	use	of	DMARDs	is	comparable	in	both	young	and	old	
RA	patients	[23,	24].	The	classic	DMARD	use	varies	from	12	to	97.3	%	and	decreases	with	age	
[37].	Combinations	of	synthetic	DMARDs	are	also	used	less	often	[37,	38].		
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But	 is	 this	 always	 justified?	 As	 outlined,	 these	 patients	 have	 more	 comorbidities,	
polymedications,	 often	 impaired	 renal	 clearance	 and	 hepatic	 function.	 But	 independently,	
age	considerations	may	erroneously	result	 into	automatically	perceiving	elderly	patients	as	
being	frail	and	unable	to	tolerate	the	medications,	and	thus	undertreating	them	[39].			
Methotrexate	 is	the	DMARD	of	choice	 in	half	 [40]	to	two	thirds	of	elderly	RA	patients,	but	
tolerability	seems	to	be	lower	with	about	30	to	50	%	of	patients	experiencing	adverse	effects	
leading	 to	 treatment	discontinuation	 [39].	This	pivotal	drug	works	 in	 synergy	with	biologic	
agents,	 increasing	 their	 efficacy,	 and	 older	 patients	 receiving	 combination	 therapy	
(methotrexate	and	anti-TNF)	have	higher	persistence	than	those	on	biologics	monotherapy,	
with	the	strongest	associations	being	observed	for	infliximab	and	adalimumab	[41].		
Glucocorticoid	use	in	older	patients	 is	significantly	higher	than	in	younger	patients	with	RA	
[23,	22,	38,	37,	29,	27,	42],	but	is	not	associated	with	achievement	of	low	disease	activity	or	
remission	 [29,	 43].	 Furthermore,	 the	 risk	 of	 infection	 in	 elderly	 patients	 taking	 even	 low	
doses	 (equivalent	 of	 ≤	 5	mg	 of	 prednisolone)	 of	 glucocorticoids	 is	 notably	 higher	 than	 in	
those	taking	any	synthetic	DMARD	and	is	twice	as	high	as	in	those	exposed	to	anti-TNF	agent	
[30].				
Despite	 fulfilling	 the	 treatment	 criteria,	 the	 biologics	 are	 used	 less	 frequently	 and	 older	
patients	have	to	wait	longer	until	such	treatment	is	initiated	[44].	However,	the	overall	use	
of	biologics	 in	the	elderly	RA	population	 is	 increasing	[45].	The	use	of	anti-TNF	agents	also	
decreases	 with	 age	 varying	 from	 41	 to	 25%	 [39,	 37,	 45,	 44],	 not	 exceeding	 6%	 in	
octagenarians	 [38],	 according	 to	 some	 studies.	 	 The	discontinuation	 rate	 is	 comparable	 to	
the	 young	 RA	 population	 with	 half	 of	 patients	 over	 65	 years	 stopping	 the	 treatment	 for	
various	reasons	(adverse	effects	and	inefficacy)	[43].			
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3.1	Anti-TNF	α	agents	in	older	RA	patients		
Targeting	 the	pro-inflammatory	 cytokine	TNF	has	dramatically	 changed	 the	 treatment	and	
outcome	of	patients	with	different	auto-immune	or	auto-inflammatory	disease,	in	particular	
those	with	RA.	 TNF	 is	 a	 cytokine	 produced	by	 different	 cells	 types	 including	macrophages	
and	T	cells	that	promotes	synovial	inflammation.	Both	soluble	receptors	(etanercept)	as	well	
as	 different	 antibodies	 (infliximab,	 adalimumab,	 golimumab	 and	 certolizumab	 pegol)	 have	
been	 developed	 as	 drugs.	 It	 is	 not	 surprising	 that	 the	 elderly	 population	 is	 largely	
underrepresented	in	the	randomized	control	trials,	achieving	at	best	12-22%	in	the	RA	study	
groups	[46]	Moreover,	these	patients	are	rarely	stratified	and	little	 information	is	available	
about	the	“very	elderly”	(75	years	and	older)	in	particular.	Retrospective	analyses	and	data	
from	patients	subsets	in	clinical	trial	may	suffer	from	selection	bias.	In	particular,	for	clinical	
trials,	patients	with	less	comorbidities	and	low	infection	risk	were	probably	selected.		
Gradually	 more	 and	 more	 data	 on	 anti-TNF	 therapy	 in	 the	 senior	 RA	 population	 are	
appearing	 not	 only	 from	 clinical	 trials	 and	 their	 secondary	 analyses,	 but	 also	 from	 large	
prospective	 and	 retrospective	 cohort	 studies.	 Most	 of	 the	 information	 is	 available	 for	
etanercept,	 followed	by	 infliximab	and	adalimumab.	Practically	no	 information	 is	 available	
on	 the	 “new”	 anti-TNFα	 agents:	 golimumab	 and	 certolizumab	 pegol	 in	 the	 elderly	 RA	
patients,	 most	 likely	 because	 these	 drugs	 were	 marketed	 much	 later	 than	 etanercept,	
infliximab	and	adalimumab.		
3.1.1		Efficacy	
Elderly	 patients	 seem	 to	 have	 a	 less	 robust	 response	 to	 anti-TNF	 therapy	 as	 compared	 to	
younger	 RA	 patients.	 	 However,	 head	 to	 head	 comparison	with	 younger	 RA	 population	 is	
rare	and	only	a	few	studies	are	available	[28,	47,	48,	46]	.						
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Several	studies	demonstrate	that	age	may	be	a	negative	predictor	of	good	response	[43,	46]		
and	 remission	 [23].	 Interestingly,	 according	 to	 the	British	 cohort	 (BSRBR),	 the	age	and	 the	
baseline	DAS28	are	not	predictive	of	response,	while	a	 lower	baseline	HAQ	is	predictive	of	
remission	[49].		Further,	in	a	Dutch	cohort	(DREAM),	the	elderly	patients	had	higher	baseline	
disease	activity	and	experienced	less	improvement	in	their	disease	activity	scores	with	20%	
less	 patients	 reaching	 good	 EULAR	 (European	 League	 against	 Rheumatism)	 response	 and	
remission	criteria	[50].	According	to	others,	TNF-α	blockers	seem	to	be	equally	effective	 in	
the	 young,	 elderly	 and	 very	 elderly	 (≥	 75	 years	 old)	 population	 on	 disease	 activity	 and	
radiographic	 progression,	 with	 best	 results	 seen	 in	 patients	 on	 combination	 therapy	 with	
methotrexate	[47,	42,	28,	51].		
Several	post	hoc	analyses	of	 late	RA	(LRA),	early	RA	(ERA)	and	the	TEMPO	etanercept	trials	
[52-55],	 evaluating	 its	 efficacy	 in	 the	 elderly	 [46,	 48,	 47,	 56]	 demonstrated	 that	 older	
patients	 had	 similar	 or	 only	 slightly	 lower	 ACR	 responses,	 particularly	 the	 ERA	 group.	
Etanercept	 was	 equally	 effective	 on	 radiological	 progression	 in	 both	 groups	 [46].		
Independently,	the	disease	duration	correlates	with	lower	rates	of	ACR50	,	ACR70	responses	
and	remission	[57].	
Most	 studies	 suggest	 that	 improvement	 in	 physical	 functioning	 is	 less	 pronounced	 in	 the	
elderly,	resulting	in	higher	HAQ	and	worse	functional	outcome	[42,	28,	51,	50].		In	contrast,	
the	secondary	analysis	of	etanercept	trials	showed	similar	changes	in	the	HAQ	scores	in	both	
age	 groups,	 but	 the	 overall	 baseline	 and	 endpoint	 HAQ	 scores	were	 higher	 in	 the	 elderly	
subjects	 [46].	 As	 for	 the	 oldest	 geriatric	 subgroup	 (≥	 75	 y.o.),	 they	 seem	 to	 have	 no	
functional	improvement	at	all	at	the	group	level	[42].		
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Finally,	biologics	treatment,	in	particular	the	use	of	anti-TNF	therapy	may	have	effects	on	the	
immunosenescence	 phenotype	 in	 RA	 discussed	 above.	 Anti-TNF-alpha	 in	 patients	with	 RA	
seems	 to	 restore	 telomerase	 expression	 in	 T	 lymphocytes,	 thus	 delaying	 RA	 induced	
premature	T	senescence	[58].	
3.1.2.Tolerability	and	safety	
Just	 like	 in	 young	 patients,	 anti-TNF	 therapy	 is	 usually	 well	 tolerated	 in	 the	 elderly.	 This	
translates	 into	 good	 but	 not	 optimal	 drug	 survival	 rates	 with	 some	 differences	 between	
specific	products	 [43].	A	 recent	meta-analysis	confirms	 this	data	with	drug	discontinuation	
rate	 (for	all	 the	TF-alpha	blockers	pooled)	gradually	 increasing	over	 time	and	 reaching	48-
52%	after	4	 years	of	 treatment.	 In	 this	 study	 the	drug	 survival	was	highest	 for	etanercept	
with	 only	 40%	 discontinuation	 rate	 at	 4	 years.	 Of	 note,	 the	 age	 did	 not	 predict	
discontinuation	 for	 any	 causes,	 including	 adverse	 effects	 or	 a	 lack	of	 efficacy.	 The	disease	
duration	did	however	predict	a	higher	discontinuation	for	adverse	effects	[59].		According	to	
the	Swiss	(SCQM-RA)	and	Dutch	(DREAM)	cohorts	the	drug	discontinuation	rates	also	appear	
to	be	similar	 in	both	young,	elderly	[42,	50]	and	very	elderly	(≥	75	years)	[42]	with	roughly	
quarter	of	patients	stopping	the	treatment	within	the	observation	time.	According	to	others	
however,	 the	 overall	 discontinuation	 rate	 is	 higher	 in	 senior	 patients	 and	 this	 is	 due	 to	
adverse	effects,	 the	efficacy	being	the	same	[60,	56,	51,	61].	Drug	survival	 is	an	 important	
proxy	 to	 assess	 drug	 efficacy	 and	 side	 effects.	 Interestingly,	 equivalent	 drug	 survival	 but	
lower	drug	response	in	elderly	RA	suggests	that	drug	survival	may	be	a	good	parameter	to	
follow	 among	 elderly	 RA	 patients.	 Other	 confounding	 factors	 that	 could	 be	monitored	 to	
prove	 biological	 safety	 and	 efficacy	 of	 biologics	 in	 this	 particular	 population	 are	 largely	
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missing	 (such	as	 steroid	decrease).	Drug	adherence	 is	 significantly	higher	 in	older	patients	
concomitantly	taking	methotrexate	[41,	46].			
Pooled	data	 from	elderly	patients	with	RA,	psoriatic	arthritis	and	spondyloarthritis	 treated	
with	etanercept,	revealed	no	difference	in	overall	adverse	effects	with	the	young	group	(83.3	
vs	77.1%),	but	the	rate	of	serious	adverse	effects	was	higher	in	the	elderly	(29%,	compared	
to	14.3	in	aged	≤65	years).	Interestingly,	secondary	analysis	of	the	etanercept	trials	revealed	
slightly	 higher	 rate	 of	 adverse	 effects	 in	 the	 older	 patients,	 however	 comparable	 to	 the	
control	groups	[46].	
Advanced	age	 (≥	80	years),	diabetes	mellitus	and	use	of	glucocorticoids	are	additional	 risk	
factors	of	adverse	effects,	in	particular	for	infections.	According	to	Iwanaga	et	al,	the	overall	
rate	varied	 from	31.6%	 in	all	RA	patients	 (treated	with	DMARDs	and/or	biologics)	younger	
than	70	years	old	and	reached	50%	in	the	very	elderly	(≥	80	years)	[40].		
Infection	 is	 effectively	 the	most	 common	 relevant	 adverse	 effect	 of	 the	 anti-TNF	 therapy,	
most	frequently	being	respiratory	tract	infections,	especially	pneumonia,	herpes	zoster	and	
cellulitis	[46,	40,	56,	30].	The	overall	rate	of	infections	seems	to	be	similar	in	the	young	and	
the	 elderly.	 But	 the	 rate	 of	 serious	 infections	 (requiring	 hospitalisation,	 IV	 antibiotics	 or	
resulting	 in	death)	 is	higher	 in	the	senior	RA	patients	treated	with	these	biologics	 [30,	56].		
The	 incidence	 of	 serious	 infections	 is	 20%	 higher	 in	 those	 exposed	 to	 anti-TNF	 agents,	
especially	 in	 the	 first	 6	 months	 of	 treatment,	 without	 significant	 difference	 between	
different	 molecules	 (infliximab/adalimumab/etanercept)	 [62].	 According	 to	 another	
comparative	study,	the	risk	is	threefold	higher	in	the	elderly	RA	patients.	Even	after	adjusting	
for	potential	confounders,	it	is	still	higher	for	infliximab	than	for	etanercept	and	is	greatest	3	
months	after	treatment	 initiation	[63].	Schneeweiss	et	al	however	found	no	increased	rate	
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of	 serious	 infections	 in	 the	 elderly	 RA	 patients	 treated	 with	 anti-TNF	 agents	
(infliximab/adalimumab/etanercept),	 after	 adjustment	 for	 other	 confounders	 including	
disease	 severity	 [64].	 Although	 the	 TNF-α	 agents	 increase	 the	 incidence	 of	 infection,	 as	
mentioned	 earlier	 steroid	 exposure	 and	 previous	 infection	 are	 also	 important	 risk	 factors	
[30,	64,	65].	
Herpes	zoster	infection	(HZV)	is	one	of	the	most	common	adverse	effects	in	the	elderly	RA	
patients	and	deserves	a	special	attention.		Age	and	glucocorticoid	use	are	independent	risk	
factors	 for	 HZV	 infection	 [66,	 67].	 According	 to	 a	 retrospective	 cohort	 study	 based	 on	
Medicare	insurance	data,	RA	patients	suffering	from	HZV	infection	were	slightly	older	(mean	
age	67	vs	64	years)	and	more	often	used	glucocorticoids.	As	for	the	biologics,	the	adjusted	
incidence	rate	of	HZV	was	comparable	 for	all	 the	anti-TNF	agents,	albeit	slightly	higher	 for	
certolizumab	[68].	The	estimated	rate	in	the	senior	patients	is	around	6.8%	[40].	[66]	
With	regards	to	tuberculosis	(TB),	the	patients	included	in	RCTs	after	a	screening	for	latent	
infection,	 did	 not	 seem	 to	 have	 a	 higher	 incidence	 than	 the	 control	 groups	 or	 general	
population	 [69,	 70].	 	 As	 for	 the	 elderly,	 no	 cases	 of	 TB	 were	 reported	 in	 the	 secondary	
analysis	 of	 etanercept	 trials	 [56,	 46].	 Another	 population-based	 study	 reported	 very	 low	
incidence	of	TB	in	the	elderly	patients	with	RA	(0.05	event/1000	patient-years)[30].		
As	discussed	earlier,	 rheumatoid	arthritis	 is	associated	with	higher	 risk	 for	certain	 types	of	
cancer,	 including	 lymphoma	 and	 non-melanoma	 skin	 cancer	 (NMSC).	 But	 do	 the	 TNF-
blockers	 further	 increase	 this	 risk?	 This	 question	 was	 addressed	 in	 a	 large	 retrospective	
cohort	 study	 [71].	Anti-TNF	 therapy	did	not	 seem	 to	 increase	 the	 risk	of	 lymphoma	 (any),	
solid	tumors	or	NMSC		in	both	primary	and	secondary	analysis	in	young	or	the	elderly	(≥	65),	
although	the	mean	follow-up	time	was	only	1	year.	Again,	 in	the	secondary	analysis	of	the	
	
	
15	
etanercept	 trials	 (LRA,	 ERA	 and	 TEMPO)	 the	 cancer	 rate	 in	 the	 older	 RA	 patients	 did	 not	
differ	 between	 the	 etanercept	 and	 control	 groups[56,	 46,	 61].	 NSAIDs,	 glucocorticoid	 use	
and	a	history	of	solid	or	haematologic	cancer	are	independent	risk	factors	[35].	In	the	same	
cohort,	 cancer	was	 the	 second	 cause	 of	mortality	 (lung	 cancer	 followed	 by	 leukemia	 and	
non-Hodgkin	lymphoma),	and	it	was	50	%	higher	than	in	population	controls	[32].				
Elderly	RA	patients	have	more	cardiovascular	comorbidities	and	a		higher	cardiovascular	risk,	
compared	 to	 younger	 patients.	 The	 emerging	 picture	 on	 cardiovascular	 problems	 such	 as	
myocardial	 infarction	 and	heart	 failure	 in	 patients	 treated	with	 anti-TNF	 is	 	 not	 clear.	 The	
variable	 presence	 of	 comorbidities	 and	 risk	 factors	 in	 this	 population	 complicates	 the	
analysis.	Only	 few	studies	addressing	this	 interesting	subject	 in	 the	elderly	RA	patients	are	
available,	mostly	retrospective	cohort	studies	[72-75]	.	According	to	a	recent	publication,	the	
patients	treated	with	the	anti-TNF-alpha	agents	(pooled	data	for	adalimumab,	certolizumab,	
etanercept,	golimumab	and	infliximab)	are	at	28%	higher	risk	of	acute	myocardial	infarction	
(AMI),	 compared	 to	 those	 treated	 with	 abatacept	 but	 overall	 rates	 may	 be	 considered	
relatively	low	for	the	age	group	[72].		
As	 for	 the	 heart	 failure	 in	 elderly	 RA	 patients,	 the	 role	 of	 TNF-alpha	 blockers	 remains	
uncertain.	Of	note,	RA,	independently	of	treatment	strategies,	is	associated	with	higher	risk	
of	 heart	 failure,	 higher	 disease	 activity	 and	 disease	 duration	 of	more	 than	 10	 years	 being	
independent	 risk	 factors	 [76].	 In	a	 subgroup	analysis	Solomon	et	al	 showed	 that	 the	heart	
failure	risk	in	the	elderly	RA	patients	(>65	y.o.)	treated	with	TNF-alpha	antagonists	was	not	
increased	and	was	even	 slightly	 lower	 compared	 to	 those	 treated	with	 synthetic	DMARDs	
(HR	0.75)	[75].	According	to	Nurmohamed	et	al,	every	6	months	of	anti-TNF	treatment	were	
associated	with	a	13%	reduction	of	cardiovascular	event	risk	 in	patients	aged	50	years	and	
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older,	 but	 elderly	 patients	 (>	 65	 y.o.)	were	 underrepresented	 in	 this	 study	 (3.2%)	 [74].	 In	
another	 study	 however,	 after	 adjustment	 for	 other	 confounders	 such	 as	 age,	 race	 and	
previous	 heart	 failure	 (HF),	 the	 TNF	 blockers	 were	 associated	 with	 the	 increased	 risk	 of	
hospitalization	for	the	HF	(HR	1.61)	[73].	According	to	others,	etanercept	was	not	associated	
with	 the	 higher	 rates	 of	 cardiovascular	 events	 [61].	 	 	Most	 of	 these	 studies	 unequivocally	
mention	 glucocorticoids	 as	 an	 important	 dose-dependent	 risk	 factor	 for	 cardiovascular	
morbidity	[72,	74,	75]		,	an	observation	that	may	influence	treatment	strategy	decisions.	
Demyelinating	disorders	have	rarely	been	reported	in	patients	treated	with	anti-TNF.	In	the	
post	 hoc	 analysis	 of	 several	 trials	 they	were	 all	 seen	 in	 subjects	 aged	 ≤	 65	 years	 [56,	 61].	
Thus,	there	is	no	clearly	increased	risk	in	the	elderly	population.		
Although	it	is	difficult	to	come	up	with	a	clear	and	undisputed	conclusion,	there	is	sufficient	
evidence	 to	 support	 the	 efficacy	 of	 anti-TNF	 strategies	 in	 elderly	 RA	 patients	 and	 to	
incorporate	 these	 strategies	 into	 a	management	 plan	 for	 the	 disease	 that	 is	 no	 different	
from	the	approach	in	the	younger	patients,	in	particular	taking	into	account	that	no	specific	
safety	 concern	 has	 been	 identified	 that	 would	 be	 strongly	 different	 from	 what	 is	 to	 be	
expected	in	the	population	of	interest.	
3.2	“Other	biologics”,	beneficial	for	the	elderly	with	RA?	
The	 treatment	 options	 for	 rheumatoid	 arthritis	 have	 dramatically	 changed	 over	 the	 last	
decade.	 Different	 potential	 targets	 have	 been	 identified	 and	 translated	 into	 therapeutic	
strategies	 that	 go	 beyond	 the	 first	 successful	 approach	 of	 inhibiting	 TNF.	 However,	
compared	to	the	data	that	provide	some	insights	 into	the	use	of	anti-TNF	agents	 in	elderly	
patients,	 there	 is	 relatively	 little	 information	 available	 about	 the	 use	 of	 tocilizumab,	
rituximab	and	abatacept	in	the	older	RA	population.			
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Despite	 their	 young	 age,	 these	 drugs	 established	 a	 solid	 ground	 in	 the	 treatment	 of	
rheumatoid	arthritis	and	proved	their	efficacy	and	safety,	comparable	to	the	anti-TNF	agents	
[77-80].			
3.2.1. Tocilizumab	
Tocilizumab	 is	 a	 humanized	monoclonal	 antibody	 against	 the	 interleukin	 6	 (IL-6)	 receptor	
[77,	 78,	 81].	 Not	 unexpectedly,	 most	 of	 the	 pivotal	 clinical	 trials	 included	 a	 majority	 of	
patients	 younger	 than	 65	 years.	 Tocilizumab	 seemed	 to	 be	more	 effective	 in	 combination	
with	 methotrexate	 in	 young	 patients	 [81,	 78].	 In	 the	 elderly,	 the	 combination	 with	
methotrexate	was	not	associated	with	greater	treatment	persistence	[41].		
The	concept	of	blocking	the	IL-6	pathway	in	the	older	RA	patients	could	provide	a	theoretical	
advantage,	taking	into	account	age-related	pro-inflammatory	changes,	often	higher	baseline	
disease	activity	and	higher	CRP	 levels	observed	 in	 the	elderly	 [82,	83].	Surprisingly	 for	 this	
assumption,	 younger	 age	 seems	 to	 be	 predictive	 of	 good	 EULAR	 response	 [81].	 Indeed,	
according	 to	Pers	et	 al.	 [84]	 a	 significantly	 smaller	proportion	of	 elderly	RA	patients	has	a	
good	EULAR	 response	 (40.1%	vs	 61%).	 The	moderate	 EULAR	 response	 as	well	 as	 the	drug	
survival	were	found	similar	in	both	age	groups.			
	About	half	of	the	patients	treated	with	tocilizumab	experience	some	adverse	effects	[85,	78,	
84],	 the	most	 common	being	 infections	and	allergic	 reactions.	 	 The	most	 frequent	 serious	
infections	 are	 pneumonia	 and	HZV,	 and	 the	 overall	 risk	 appears	 comparable	 to	 that	 seen	
with	other	biologics	[10,	84,	86].	The	elevation	of	liver	enzymes,	reduction	in	the	neutrophil	
count	and	 lipid	changes	 (increase	 in	 levels	of	cholesterol	and	triglycerides)	 [87],	specific	 to	
this	 particular	 drug	 [77,	 78,	 81],	may	 be	 of	 concern	 in	 the	 elderly	 RA	 patients.	 However,	
compared	 to	other	biologics,	 the	elderly	patients	 treated	with	 tocilizumab	do	not	seem	to	
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have	 an	 increased	 risk	 of	myocardial	 infarction	 and	 even	 have	 a	 reduced	 risk	 of	 coronary	
heart	 disease	 outcome	 (myocardial	 infarction,	 percutaneous	 coronary	 intervention	 or	
coronary	artery	bypass	grafting)	[72].	Age,	statin	use,	higher	cholesterol	levels	and	history	of	
cardiac	 disorders,	 often	 encountered	 in	 seniors,	 are	 independent	 predictors	 of	
cardiovascular	events	in	patients	treated	with	tocilizumab	[88].	An	association	was	observed	
between	 the	 baseline	 total	 cholesterol:high-density	 lipoprotein	 cholesterol	 ratio	 and	 an	
increased	 risk	 of	major	 adverse	 cardiovascular	 events.	 This	 risk	while	 receiving	 treatment,	
however,	was	inversely	associated	with	control	of	disease	activity	but	not	with	lipid	changes,	
suggesting	 indeed	 that	 better	 control	 of	 inflammation	 may	 at	 least	 partially	 offset	 an	
eventual	 increased	 risk	 due	 to	 drug-associated	 dyslipidemia	 [88].	 	 No	 TB	 cases	 were	
observed	in	RCTs	in	patients	treated	with	tocilizumab	[69].		
3.2.2. Rituximab	
Rituximab	is	a	cell-depleting	anti-CD20	monoclonal	antibody	that	specifically	targets	B	cells	
without	affecting	the	B	lineage	stem	cell	pool	and	the	IgG	producing	plasma	cells.	The	clinical	
trial	and	prospective	cohorts	included	patients	above	60	or	65	years	but	little	attention	has	
been	paid	to	the	elderly	subgroups	in	the	subsequent	analyses.	Nevertheless,	there	is	some	
evidence	that	the	proportion	of	good	responders	in	the	elderly	and	especially	very	elderly	(≥	
75years)	 is	 significantly	 lower	 compared	 to	 younger	 patients.	 The	 improvement	 in	 DAS28	
disease	 activity	 scores	 is	 significantly	 lower	 in	 the	 patients	 aged	 75	 years	 and	 older	
compared	 to	 patients	 between	 65	 and	 75.	 However,	 in	 the	 same	 cohort	 discontinuation	
rates	were	not	different	between	age	groups	[89].	In	the	German	Gerinis	cohort	in	contrast	
no	difference	in	outcome	were	found	between	groups	of	patients	younger	and	older	than	60	
years	[90].	Similarly	in	this	cohort,	adverse	events	were	not	different	between	age	groups.		
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Long-term	 analyses	 of	 the	 clinical	 trials	 and	 within	 real-life	 cohorts	 indicate	 that	 the	
withdrawal	rate	for	this	drug	is	relative	low	e.g	just	over	30%	after	two	years	in	a	large	real-
life	 cohort	 [89]	 and	mainly	 occurring	 during	 the	 first	 two	 courses	 in	 around	 one-third	 of	
patients,	irrespective	of	age	(even	in	the	very	elderly,	≥	75	years)	[91].	Comparisons	of	drug	
survival	among	different	biological	agents	is	not	easy	as	the	administration	interval	may	play	
a	 role	 in	 the	 patient’s	 or	 physician’s	 decision	 to	 stop	 a	 given	 treatment,	 but	 also	 in	 the	
recording	 and	 analysis	 of	 drug	 survival	 data.	 This	 is	 particularly	 the	 case	 with	 rituximab	
where	 intervals	of	 treatment	have	been	determined	by	reappearance	of	symptoms	and	of	
the	target	cells.	
Tolerance	 and	 safety	 of	 rituximab	 in	 elderly	 patients	with	 RA	 does	 not	 appear	 to	 be	 very	
different	from	that	in	younger	patients.	The	most	frequent	adverse	effects	include	infusion	
reactions	 and	 infections,	 predominantly	 of	 lower	 respiratory	 and	 genitourinary	 tract	 [91].	
The	rate	of	Herpes	Zoster	attacks	is	similar	that	seen	with	other	biologics	[86].	Just	 like	for	
anti-TNF	agents,	some	data	suggest	that	severe	infections	are	more	frequent	in	the	elderly	
(19.5%)	and	very	elderly	 (26.5%),	compared	to	 less	than	5%	in	the	young	subjects	[89]	but	
these	data	were	not	confirmed	in	the	German	cohort.	Only	two	cases	of	TB	were	reported	in	
the	all-exposure	population	treated	with	rituximab	in	the	clinical	trial	program		[69].	Low	IgG	
levels	induced	by	or	associated	with	the	treatment,	although	rare	(4%),	are	associated	with	
higher	 rates	 of	 severe	 infection	 [91].	 Also,	 no	 evidence	 of	 increased	 malignancy	 or	
cardiovascular	 risk	 has	 been	 reported	 in	 patients	 treated	 with	 rituximab	 [91].	 Not	
unexpectedly	 and	 relevant	 for	 elderly	patients,	 humoral	 responses	 towards	pneumococcal	
and	 influenza	 vaccination	 are	 reduced	 in	 patients	 who	 receive	 rituximab.	 However,	 as	
concluded	 in	 a	 recent	 meta-analysis,	 vaccination	 still	 provides	 protection	 in	 a	 number	 of	
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cases	 and	must	be	proposed	 to	every	RA	patient,	 and	 the	 vaccination	 schedule	 should	be	
adapted	to	the	current	or	future	treatment	[92].		
3.2.3. Abatacept		
Abatacept	or	CTLA4-Ig	is	a	selective	modulator	of	T	cell	co-stimulation.	Data	about	the	use	of	
abatacept	 in	 the	 elderly	 population	 with	 rheumatoid	 arthritis	 are	 scarce.	 Based	 on	 the	
limited	 available	 data	 sets	 age	 does	 not	 seem	 to	 influence	 the	 drug’s	 effect	 on	 disease	
activity	[93,	83].		
According	 to	 a	 recent	 prospective	 cohort,	 remission,	 good	 and	 moderate	 responses	 are	
similar	in	young,	elderly	(65-74y.o.)	and	very	elderly	patients	(>75	y.o.)	at	12	and	24	months.	
Having	a	higher	baseline	activity,	the	very	elderly	had	a	lower	probability	of	good	response	
at	6	months,	but	at	12	months	the	difference	was	no	longer	statistically	significant	[83].	Drug	
survival	rates	from	extension	cohorts	of	the	clinical	trials	and	different	cohorts	under	study	
indicate	 relatively	 low	 short	 term	discontinuation	 rates	 [93-98].	Again,	 little	 information	 is	
available	on	the	subpopulation	of	elderly	patients.	The	age	does	not	seem	to	influence	the	
drug	survival,	with	averagely	tree-quarters	of	patients	stopping	their	treatment	at	least	once	
in	a	24	month	period	in	all	age	groups	(<65	years,	64-74	years	and	≥	75	years)	[83].	However,	
the	 discontinuation	 for	 lack	 of	 effectiveness	 decreases	 and	 discontinuation	 for	 adverse	
effects	 increases	with	 age.	 Co-treatment	with	methotrexate	 does	 not	 appear	 to	 influence	
the	treatment	persistence	in	older	patients	based	on	a	Medicare	dataset	based	retrospective	
study	[41].			
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Again,	little	specific	safety	data	on	the	elderly	patients	is	available	in	the	literature.	However,	
the	 EMA	 and	 FDA	 documents	 do	 report	 that	 the	 frequencies	 of	 serious	 infection	 and	
malignancy	relative	to	placebo	among	abatacept-treated	patients	over	age	65	in	the	clinical	
were	higher	 than	among	 those	under	age	65.	The	overall	 incidence	of	malignancies	 in	 the	
clinical	 development	 program	 of	 abatacept	 was	 not	 higher	 than	 expected	 in	 similar	
rheumatoid	arthritis	cohorts	 [99].	According	to	Lahaye,	 in	patients	 treated	with	abatacept,	
the	 rate	 of	 adverse	 effects,	 especially	 serious	 infection	 increases	 with	 age	 [83],	 the	most	
common	 infection	sites	being	 	 in	bronchopulmonary,	genitourinary	systems	and	the	 joints.	
French	 real-life	 cohort	 study	 associated	 age	 and	 history	 of	 previous	 serious	 or	 recurrent	
infections	with	 a	 higher	 risk	 of	 serious	 infections	 suggesting	 a	 hazard	 risk	 of	 1.44	 over	 10	
years	 for	 age	 [100].	 	 The	 risk	 for	 herpes	 zoster	 flares	 was	 relative	 low	 with	 an	 absolute	
incidence	 rate	 of	 of	 1.87	 /	 100	 patient	 years	 [86].	 The	 authors	 did	 not	 detect	 differences	
among	different	biologics.	No	cases	of	TB	reactivation	were	reported	for	this	drug.	Of	note,	
vaccination	strategies	may	be	more	challenging	in	abatacept-treated	patients.	Combination	
of	 abatacept	 and	 a	 conventional	 DMARD	 significantly	 reduced	 the	 response	 towards	 the	
2009	 influenza	 vaccine	 [101].	 Similar	 data	 have	 been	 proposed	 for	 vaccination	 against	
pneumococcus	pneumoniae	[102,	103].	
Although	 abatacept	 appears	 an	 interesting	 option	 for	 elderly	 patients	 based	 on	 its	 safety	
profile	 and	 sustained	 benefit,	 it	 is	 clear	 that	 specific	 data	 are	 largely	missing.	 Taking	 into	
account	 the	working	mechanism	 of	 this	 drug,	 further	 studies	with	 additional	 translational	
analyses	 of	 the	 T	 cell	 repertoire	 and	 eventual	 changes	 induced	 by	 this	 molecule	 when	
treating	elderly	rheumatoid	arthritis	patients	is	of	great	interest.	The	prescribing	information	
warning	that	patients	over	65	should	be	better	monitored	for	infection	and	malignancy	does	
not	 appear	 to	 dictate	 a	 strategy	 that	would	 be	 different	 than	 that	 for	 the	 other	 biologics	
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discussed	 in	 this	 review.	 The	 data	 on	 vaccines	 do	 not	make	 vaccination	 in	 patients	 under	
treatment	 useless	 but	 do	 suggest	 that,	 whenever	 possible,	 the	 vaccination	 status	 of	
rheumatoid	arthritis	patients	should	be	optimized	before	starting	therapy	with	abatacept.	
	
4. CONCLUSION	
In	conclusion,	although	elderly	RA	patients	more	often	suffer	from	comorbidities	and	are	at	
higher	risk	of	 infections	and	cardiovascular	disease,	they	often	have	higher	disease	activity	
and	 functional	 disability.	 Unfortunately	 they	 are	 largely	 underrepresented	 in	 the	 clinical	
trials,	often	those	with	less	comorbidities	are	selected.	Older	RA	patients	seem	to	have	a	less	
robust	 response	 to	biologics	 and	are	 less	 likely	 to	 achieve	 remission,	 but	 the	 treatment	 is	
generally	 well	 tolerated	 with	 withdrawal	 rates	 comparable	 to	 the	 young	 population.	 The	
drug	survival	rate	is	similar	between	different	molecules	and	does	not	seem	to	be	influenced	
by	age.		However,	biologics	are	prescribed	less	and	glucocorticoids	more	often	in	this	group.	
The	 rate	 of	 adverse	 effects	 is	 similar	 to	 the	 younger	 RA	 patients,	 but	 the	 rate	 of	 serious	
adverse	 effects,	 especially	 serious	 infections,	 is	 higher	 in	 the	 elderly	 and	 especially	 very	
elderly.	From	this	point	of	view,	in	light	of	 latest	research	and	current	evolutions	in	clinical	
practice,	 tapering	 and	 stopping	 of	 biologicals	 in	 elderly	 patients	 in	 remission	 might	 be	
beneficial	 in	 reducing	 the	 adverse	 effects.	 To	 conclude,	 one	 should	 be	 cautious	 treating	
seniors	with	 rheumatoid	 arthritis	 and	meticulously	 evaluate	 the	 pros	 and	 the	 cons	 of	 the	
biologic	 treatment.	 	 However,	 the	 age	 alone	 should	 not	 limit	 our	 therapeutic	 options.	 As	
experience	 is	 growing	 the	 need	 of	 a	 true	 comparison	 between	 biologic	 DMARDs	 users	 in	
elderly	and	very	elderly	RA	patients	versus	non-biologic	users	with	matching	procedures	can	
be	considered	a	priority.	
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